UNIFOB AS, Dental Biomaterials Adverse Reaction Unit
Bergen, NO-5009, Norway
NCT Number: NCT00346944
The aim of the project is to study changes in symptom load after removal of all dental amalgam restorations in patients with symptoms allegedly related to amalgam.
Looking for future studies?
Notify Me25 year–55 year
All sexes
Interventional
Phase 4
Bergen, NO-5009, Norway
Patients referred from dentists and physicians in the period 1993 to 1999 to the Dental Biomaterials Adverse Reaction Unit, Department of Health, UNIFOB AS, for symptoms related to amalgam restorations are randomized into treatment group (n=20) or reference group (n=20). All patients in the treatment group are followed 3, 12, 36 and 60 months after completion of amalgam removal with questionnaires on health outcomes, Minnesota Multiphasic Personality Inventory-2 (MMPI-2) and laboratory tests.
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Removal of dental amalgam restorations by patient's own dentist. Fillings will be replaced with e.g. resin based filling material, metalloceramic restorations, and ceramic materials. Rubber dam will be used during removal of amalgam restorations.
Time frame: Five years
Time frame: Five years
Time frame: Five years
Time frame: One year
University of Bergen
Other
Health Effects From Removal of Amalgam Restorations in Patients With Symptoms Allegedly Related to Dental Amalgam - A Study of Patients Examined at the Dental Biomaterials Adverse Reaction Unit in 1993 to 1999
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT05090384
Acute Graft vs Host Disease, Adverse Effects
Los Angeles, California, United States
View Trial DetailsNCT07092384
Adverse Effects, Remifentanil
Wuhan, Hubei, China
View Trial DetailsNCT05486923
Adverse Effects, Glioma
Beijing, Beijing Municipality, China
View Trial DetailsNCT06673277
Adverse Effects, Cryotherapy
Winchester, Hampshire, United Kingdom
View Trial Details